1. Medicine

Category Archives: Medicine

Dead Island Riptide Alternative Medicine | Shiny Mushroom Cave | Fungi For Dr. Jane Location | – Video

Posted on by


Dead Island Riptide Alternative Medicine | Shiny Mushroom Cave | Fungi For Dr. Jane Location |
A video guide showing how to complete both parts of the "Alternative Medicine" quest in Dead Island: Riptide. Shows the infirmary location, where to find Dr....

By: LetsPlayCatGaming

Original post:

Dead Island Riptide Alternative Medicine | Shiny Mushroom Cave | Fungi For Dr. Jane Location | - Video

FOX Sports Supports: Johns Hopkins Medicine – Jimmy Johnson, Curt Menefee, and Joey Harrington – Video

Posted on by


FOX Sports Supports: Johns Hopkins Medicine - Jimmy Johnson, Curt Menefee, and Joey Harrington
FOX Sports Supports proudly teams up with Johns Hopkins Medicine. Johns Hopkins conducts extensive research into the causes of autoimmune diseases including ...

By: FOX Sports

Original post:

FOX Sports Supports: Johns Hopkins Medicine - Jimmy Johnson, Curt Menefee, and Joey Harrington - Video

CSU College of Veterinary Medicine and Biomedical Sciences Class of 2013 – Video

Posted on by


CSU College of Veterinary Medicine and Biomedical Sciences Class of 2013
We are proud of our 132 undergraduate, 88 master and PhD students, and 141 DVM students who received their degrees during the spring 2013 commencement weeken...

By: csuvetmedbioscience

Go here to see the original:

CSU College of Veterinary Medicine and Biomedical Sciences Class of 2013 - Video

Billings Clinic's internal medicine residency program earns accreditation

Posted on by

Its official: Billings Clinics new internal-medicine program has earned accreditation.

The program, designed totrain primary-care physicians in the region, is the first of its kind in Montana and Wyoming. It has been accredited for three years by the Chicago-based Accreditation Council for Graduate Medical Education, the maximum length of time for an initial accreditation. It was one of only four internal-medicine residency programs throughout the nation that achieved accreditation.

At full capacity, the residency program could be producing as many as six new doctors a year.

The hope is that those new doctors will choose to practice in Montana, where most counties have a shortage of primary-care physicians and 10 counties have no physician at all.

The startup investment of "several million dollars" will be underwritten by Billings Clinic, Billings Clinic Foundation and grants.

The next step is torecruit students and some faculty members. Though the formal application process won't begin until September, there has already been a "heartwarming interest from students," said Dr.Roger Bush, director of the program.

The program will open to the first class of students in July 2014. The program will feature six positions each year in the three-year curriculum, a total of 18 slots when full.

The core faculty will be composed of about two dozen Billings Clinic physicians, drawn from the hospitals 240 physicians, and nearly 100 nurse practitioners and physician assistants.

The program will not only provide training in the outpatient and hospital settings but also "will teach our methods for providing care to our rural communities through collaboration, technology, and outreach clinics, Bush said.

"Our strategy is to be a learning laboratory to providebetter care, better health, better costs and to bring joy to the work of caring for others," Bush said.

Continue reading here:

Billings Clinic's internal medicine residency program earns accreditation

BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress

Posted on by

BOTHELL, Wash., May 23, 2013 /PRNewswire/ --BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced its participation at the Terrapinn World Stem Cells & Regenerative Medicine Congress 2013 this week in London.

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Dr. Aby J. Mathew, BioLife's Senior Vice President and Chief Technology Officer, will make a presentation titled "Critical Stability and Biopreservation Considerations for Manufacturing, Storage and Clinical Delivery of Cell and Tissue Products," to the audience of executives and product development managers of commercial regenerative medicine companies. The presentation outlines the risk to clinical and commercial success of cell and tissue products due to stability limitations from the use of non-optimized storage, transport and cryopreservation freeze media. Comparative data illustrating the superior preservation efficacy of BioLife's HypoThermosol storage and shipping media, and CryoStor cryopreservation freeze media will be presented on relevant cell and tissue types.

Mike Rice, Chief Executive Officer, commented, "We continue to build traction in the high growth regenerative medicine market, and estimate that more than 65 percent of the presenting companies at this conference have adopted our best in class, clinical grade biopreservation media products. A key value-added service we provide, which directly translates into expanded product adoption, is the high quality consulting our team offers to prospective and current customers. Biopreservation outcomes such as cell and tissue shelf life, viability and recovery can greatly impact commercial potential. The combination of the efficacy and quality of our proprietary platform technology, along with our expert technical consulting services, is now recognized and highly valued in the development and commercialization of regenerative medicine products and therapies."

The regenerative medicine market is expected to grow to more than $35 billion by 2019, according to TriMark Publications' recently published "Regenerative MedicineMarkets" report. BioLife's addressable portion of the market is the demand for reagents used to store, ship and freeze source material and manufactured doses of cell-based products and therapies.

For a list of upcoming events, please visit http://biolifesolutions.com/cell-therapy/category/events/.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. The Company's proprietary HypoThermosol and CryoStor platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce biopreservation-induced cell damage and death. BioLife's enabling technology provides academic and clinical researchers, and commercial companies significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit http://www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Visit link:

BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress

BTG builds interventional medicine platform with deals

Posted on by

LONDON (Reuters) - Britain's BTG said it would make two acquisitions, one extending its expertise in liver cancer and the other a treatment for severe blood clots, to create an interventional medicine business with potential sales of $1 billion.

The company said on Thursday it had agreed to buy the targeted therapies division of Nordion Inc, for about $200 million in a deal that adds Therasphere radioactive glass beads treatment for liver cancer to its chemotherapy beads unit.

It is also buying EKOS Corp for an initial $180 million, and up to $40 million in future payments depending on achieving milestones, to gain an interventional treatment for severe blood clots.

Some of the cost of buying the Nordion unit will come from the placing of 32.8 million new shares, representing just under 10 percent of BTG's share capital.

Chief Executive Louise Makin said the deals would position BTG as a leading player in the rapidly growing interventional medicine market.

"By adding TheraSphere and EkoSonic into our current portfolio of oncology beads and Varisolve (PEM), our board's vision is to create an Interventional Medicine business with potential sales of $1 billion," she said.

(Reporting by Paul Sandle; editing by James Jukwey)

More here:

BTG builds interventional medicine platform with deals


  1. Medicine